Effectiveness of MenB-4C Vaccine Against Gonorrhea: a Systematic Review and Meta-analysis.

Details

• Alternative Title:
  The Journal of Infectious Diseases, 2025, v. 231, no. 1: Effectiveness of MenB-4C Vaccine Against Gonorrhea: a Systematic Review and Meta-analysis.
• Journal Article:
  The Journal of Infectious Diseases
• Personal Author:
  Abara, Winston E. ; Kirkcaldy, Robert D. ; Bernstein, Kyle T. ; Galloway, Eboni ; Learner, Emily R.
• Description:
  There is no licensed vaccine against gonorrhea, but Neisseria meningitidis serogroup B outer membrane vesicle-based vaccines, such as MenB-4C, may offer cross-protection against gonorrhea. This systematic review and meta-analysis synthesized the published literature on MenB-4C vaccine effectiveness against gonorrhea.
  
  We conducted a literature search of electronic databases (PubMed, Medline, Embase, Global Health, Scopus, Google Scholar, CINAHL, and Cochrane Library) to identify peer-reviewed articles published in English from 1 January 2013 to 11 September 2024 that reported MenB-4C vaccine effectiveness estimates against gonorrhea and gonorrhea/chlamydia coinfection and the duration of MenB-4C vaccine-induced protection. We estimated pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea using the DerSimonian-Laird random effects model.
  
  Eight articles met our eligibility criteria. Receipt of ≥1 dose of MenB-4C vaccine was 23% to 47% effective against gonorrhea. Two doses of MenB-4C vaccine were 33% to 40% effective against gonorrhea, and 1 dose of MenB-4C vaccine was 26% effective. MenB-4C vaccine effectiveness against gonorrhea/chlamydia coinfection was mixed, with 2 studies reporting effectiveness estimates of 32% and 44% and 2 other studies showing no protective effect. MenB-4C vaccine effectiveness against gonorrhea was comparable in people with HIV (44%) and people without HIV (23%-47%). Pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea was 32.4%. One study concluded that MenB-4C vaccine effectiveness against gonorrhea may wane approximately 36 months postvaccination.
  
  MenB-4C vaccine is moderately effective against gonorrhea in various populations. Prospective clinical trials that assess the efficacy of MenB-4C against gonorrhea, gonorrhea/chlamydia coinfection, and duration of protection are warranted to strengthen this evidence.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Gonorrhea
  • Meningococcal Vaccines
  • Vaccine Efficacy
  • Male
  • Neisseria gonorrhoeae
  • Coinfection
  • Chlamydia Infections
  • Neisseria meningitidis, Serogroup B
• Keywords:
  • MenB-4C
  • gonorrhea
  • STI vaccine
  • vaccine effectiveness
  • gonorrhea/chlamydia co-infection
  • HIV
  • meta-analysis
  • pooled vaccine effectiveness
  • OMV MenB vaccines
  • chlamydia
• Source:
  The Journal of Infectious Diseases, 2025, v. 231, no. 1
• DOI:
  https://doi.org/10.1093/infdis/jiae383
• ISSN:
  0022-1899 ; 1537-6613
• Pubmed ID:
  39082700
• Pubmed Central ID:
  PMC11782638
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Pages in Document:
  61-70 (17 pdf pages)
• Volume:
  231
• Issue:
  1
• Download URL:
  https://stacks.cdc.gov/view/cdc/262068/cdc_262068_DS1.pdf
• File Type:
  [PDF - 721.05 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:df5650439a2eb9e98eea4ecd301806f57cd722373cb199881ab8e5ed914756ed00ace607a4a5b1bc51691695231e841ef6736a81d0eebc86132ee986bac58000